Why Arrowhead Pharmaceuticals (ARWR) Is Up 7.8% After Launching Its First Dual-Gene RNAi Trial [Yahoo! Finance]
Arrowhead Pharmaceuticals, Inc. (ARWR)
Last arrowhead pharmaceuticals, inc. earnings: 2/5 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arrowheadpharma.com/investor-relations
Company Research
Source: Yahoo! Finance
silence both PCSK9 and APOC3 to address atherosclerotic cardiovascular disease caused by mixed hyperlipidemia. This marks the first time a single RNA interference molecule has been advanced into human testing to target two genes simultaneously, highlighting Arrowhead's TRiM platform as an important platform-level development in cardiometabolic drug research. We'll explore how launching this first-in-human dual-gene RNAi trial shapes Arrowhead's investment narrative around cardiometabolic innovation and platform potential. Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. For Arrowhead, the core belief is that its TRiM RNAi platform can support multiple commercially meaningful drugs across cardiometabolic and rare disease markets, not just a single asset story. REDEMPLO's recent approvals begin that transition toward a revenu
Show less
Read more
Impact Snapshot
Event Time:
ARWR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARWR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARWR alerts
High impacting Arrowhead Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ARWR
News
- Arrowhead Pharmaceuticals Inc (ARWR) Q1 2026 Earnings Call Highlights: Strong Financial ... [Yahoo! Finance]Yahoo! Finance
- Arrowhead Pharmaceuticals Q1 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter ResultsBusiness Wire
- Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million [Yahoo! Finance]Yahoo! Finance
- Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia [Yahoo! Finance]Yahoo! Finance
ARWR
Earnings
- 2/5/26 - Miss
ARWR
Sec Filings
- 2/5/26 - Form 10-Q
- 2/5/26 - Form 8-K
- 1/27/26 - Form ARS
- ARWR's page on the SEC website